Skip to main content
Nanologica logo

Nanologica — Investor Relations & Filings

Ticker · NICA ISIN · SE0005454873 LEI · 54930017L41C7P87LP22 ST Manufacturing
Open in API
Filings indexed 181 across all filing types
Latest filing 2025-10-14 Board/Management Inform…
Country SE Sweden
Listing ST NICA

About Nanologica

https://nanologica.com/

Nanologica is a life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in nanoporous silica particles for preparative chromatography, a critical step in drug production. Its core product, NLAB Saga®, is a spherical, porous silica media engineered for the large-scale purification of peptide drugs, such as insulin and GLP-1 analogues used to treat diabetes and obesity. The product's high mechanical and chemical stability provides effective purification and a long lifetime, which increases productivity and reduces costs for pharmaceutical manufacturers. Nanologica's mission is to lower the manufacturing costs of these drugs, thereby increasing patient access to life-saving treatments. The company is also developing a broader portfolio of purification media.

Recent filings

Filing Released Lang Actions
NANOLOGICA ANNOUNCES NOMINATION COMMITTEE FOR THE ANNUAL GENERAL MEETING 2026
Board/Management Information Classification · 100% confidence The document is an announcement regarding the formation of a nomination committee for the upcoming 2026 Annual General Meeting. It lists the committee members and their shareholding representation, and provides instructions for shareholders to submit proposals. This type of disclosure is a standard corporate governance announcement related to the preparation for an AGM, which falls under the category of Proxy Solicitation & Information Statement (PSI) as it pertains to the governance and procedural setup for the meeting.
2025-10-14 English
NANOLOGICAS VALBEREDNING UTSEDD INFÖR ÅRSSTÄMMAN 2026
Board/Management Information Classification · 100% confidence The document is an announcement regarding the appointment of a nomination committee (valberedning) for the upcoming 2026 Annual General Meeting. It lists the members of the committee and their shareholding representation. This type of corporate governance announcement, which precedes the actual AGM materials, is best classified as a regulatory filing (RNS) as it does not fit into specific categories like AGM-R (which are materials for the meeting itself) or PSI (proxy solicitation).
2025-10-14 Swedish
Nanologica AB (publ) Enters the Insulin Market in China
Regulatory Filings Classification · 100% confidence The document is a press release announcing a new commercial order for Nanologica AB. It describes a specific business development (entering the insulin market in China) and includes a quote from the CEO. It is not a financial report, proxy, or governance document. Since it is a general corporate announcement regarding business operations and is required to be made public under the EU Market Abuse Regulation, it falls under the general regulatory filing category.
2025-10-01 English
Nanologica AB (publ) tar sig in på insulinmarknaden i Kina
Regulatory Filings Classification · 100% confidence The document is a press release announcing a new commercial order for Nanologica AB. It details the nature of the order (2 MSEK for insulin production materials in China), provides management commentary, and includes standard corporate contact information. It concludes with a regulatory disclosure statement required by the EU Market Abuse Regulation and a link to the PDF version of the announcement. Since it is a general corporate announcement regarding business operations that does not fit into specific categories like M&A, earnings, or dividends, it is classified as a Regulatory Filing (RNS).
2025-10-01 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT Q2 2025' (Interim Report Q2 2025) for Nanologica AB. It contains comprehensive financial statements, including income statements, balance sheets, cash flow data, and management commentary on business performance for the second quarter and first half of 2025. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report (IR). Q2 2025
2025-07-10 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'INTERIM REPORT Q2 2025' for Nanologica AB. It contains comprehensive financial statements, including income statements, cash flow data, and balance sheet metrics for the second quarter and the first half of 2025. It also includes a CEO comment, business updates, and key performance indicators. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q2 2025
2025-07-10 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.